Welcome to our dedicated page for Zai Lab SEC filings (Ticker: ZLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Zai Lab’s latest 10-K means wading through hundreds of pages on oncology trial endpoints, milestone royalties, and cross-border licensing terms. Finding when executives file Form 4s before a key Phase III read-out can be equally demanding. Stock Titan’s AI-powered SEC dashboard turns that complexity into clarity.
Our platform monitors every Zai Lab quarterly earnings report 10-Q filing, Zai Lab annual report 10-K simplified, and Zai Lab 8-K material events explained the moment they hit EDGAR. Instantly see cash-runway updates, trial spend, and collaboration revenue without scrolling line-by-line. Need fast answers to “Zai Lab SEC filings explained simply” or “understanding Zai Lab SEC documents with AI”? The summary panel delivers plain-English context, key metrics, and citation links in seconds.
Stay alerted to Zai Lab insider trading Form 4 transactions. We surface Zai Lab Form 4 insider transactions real-time, flagging option exercises and open-market buys so you can assess sentiment before headlines hit. The proxy center pairs Zai Lab proxy statement executive compensation data with visual charts that benchmark R&D bonuses and equity grants against biotech peers.
- AI snapshots of pipeline milestones hidden in 10-Qs
- Side-by-side earnings trend graphs for rapid Zai Lab earnings report filing analysis
- One-click downloads of every exhibit—agreements, trial protocols, risk factors
Whether you’re gauging dilution risk, tracking Zai Lab executive stock transactions Form 4, or reviewing disclosure notes on immunology assets, Stock Titan provides the complete, continuously updated repository—decoded for actionable insight.
Zai Lab Limited has filed a Form 144 disclosing a proposed sale of 50,000 American Depositary Shares (ADS) through Fidelity Brokerage Services LLC on 08/08/2025, with an aggregate market value reported as $1,737,156.02 and 421,725,450 ADS outstanding. The notice states these ADS were acquired under options granted on 10/22/2015 and lists the acquisition and payment date as 08/08/2025 with payment in cash.
The filing also itemizes seven prior ADS sales by Ying Du between 05/09/2025 and 07/02/2025, showing transaction sizes and gross proceeds for each. The form includes the standard Rule 144 representation that the seller is not aware of any undisclosed material adverse information about the issuer.
What: Form 144 notice related to Zai Lab Limited (ZLAB) reporting a proposed sale of American Depositary Shares (ADS).
Key facts:
- Shares to be sold: 3,000 ADS
- Aggregate market value: $105,000.00
- Approximate sale date: 08/08/2025
- Exchange: NASDAQ
- Shares outstanding (issuer): 421,725,450
Acquisition: ADS were acquired on 12/30/2023 via restricted stock vesting from the issuer; consideration/ payment listed as compensation.
Other: The filing states "Nothing to Report" for securities sold in the past three months. Some filer/contact fields in the form content are not populated.
Form 144 filing: An insider of Zai Lab Ltd. (ZLAB), identified as Yajing Chen, notifies intent to sell 4,096 American Depositary Shares (ADS) through Fidelity on or after 08 Aug 2025. The block is valued at roughly US$139,305 based on current market pricing.
The shares were acquired on 25 Jun 2024 via restricted-stock vesting as compensation. Chen has already sold 9,618 ADS (US$288,540) on 02 Jun 2025 and 2,675 ADS (US$96,652) on 26 Jun 2025, bringing recent disposals to 12,293 ADS, or about US$385,192 in proceeds.
Planned and recent sales combined equal 16,389 ADS—just 0.0039% of the 421.7 million shares outstanding—indicating a negligible impact on ownership structure or float. The document contains no operational or financial performance data; it is strictly a regulatory notice of a small insider sale, which may signal mild negative sentiment but is unlikely to move the stock on size alone.
Zai Lab Limited (ZLAB) Q2 2025 10-Q highlights: Net product revenue rose 9 % YoY to $109.1 million, lifting total revenue to $110.0 million. Cost controls drove a 28 % YoY cut in operating loss to $54.9 million and shrank net loss by 49 % to $40.7 million (-$0.04/share). Six-month revenue climbed 15 % to $216.5 million, with net loss down 33 % to $89.2 million.
Growth came from VYVGART (+14 %), NUZYRA (+16 %), XACDURO and AUGTYRO launches, partly offset by a 9 % decline in ZEJULA. R&D expense fell 18 % YoY, SG&A fell 11 %, and operating cash outflow improved to -$92.7 million from -$132.3 million. Cash & equivalents surged to $732.2 million after maturing $330 million of short-term investments; short-term debt increased to $174.5 million (2.66 % avg. rate).
- Q2 gross margin ~61 % (product revenue vs. cost of product revenue).
- Shares outstanding: 1.10 billion; ADS float 421.7 million.
- Pivotal pipeline events: Fast Track for ZL-1310 (SCLC), positive Phase III data for bemarituzumab (FGFR2b gastric), PANOVA-3 success for TTFields, NMPA sNDA acceptance for repotrectinib.
- Subsequent event: doubled CMB revolving facility to RMB500 million (~$69.6 million) on 6 Aug 2025.
Despite stronger top-line momentum and disciplined spending, Zai Lab remains loss-making and dependent on capital markets and credit lines while advancing an expansive late-stage pipeline.
Zai Lab Limited (NASDAQ: ZLAB) filed a Form 144 indicating that insider Ying Du plans to sell 7,072 American Depositary Shares (ADS) on 02 July 2025 through Fidelity Brokerage Services. The proposed transaction is valued at US$249,143.73, representing roughly 0.0015 % of the company’s 486.9 million ADS outstanding, and stems from the vesting of restricted stock on 01 July 2025.
The filing also discloses that the same insider has already sold 235,729 ADS between 02 April 2025 and 30 June 2025, generating an estimated US$7.1 million in gross proceeds. These prior sales were executed in eight tranches ranging from 2,945–50,000 ADS each.
Although the absolute dollar value of the individual sale is modest relative to Zai Lab’s market capitalization, the cumulative selling pattern may be interpreted by some investors as a signal of insider profit-taking. No new operational, earnings or strategic information is provided in this filing; the document is strictly a regulatory notice satisfying Rule 144 requirements.
FAQ
What is the current stock price of Zai Lab (ZLAB)?
What is the market cap of Zai Lab (ZLAB)?
